|
CA2217373A1
(en)
*
|
1996-10-10 |
1998-04-10 |
Michael John Martin |
Benzo¬b|thiophene compounds, intermediates, formulations, and methods
|
|
AU7170898A
(en)
*
|
1997-04-30 |
1998-11-24 |
Eli Lilly And Company |
Antithrombotic agents
|
|
WO1998049161A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
DE69828522T2
(de)
|
1997-04-30 |
2005-12-15 |
Eli Lilly And Co., Indianapolis |
Antithrombotische mittel
|
|
WO1998048797A1
(en)
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6271227B1
(en)
|
1997-04-30 |
2001-08-07 |
Eli Lilly And Company |
Antithrombotic Agents
|
|
CA2287984A1
(en)
|
1997-05-01 |
1998-11-05 |
Gerald Floyd Smith |
Antithrombotic agents
|
|
US7008950B1
(en)
|
1997-06-05 |
2006-03-07 |
Takeda Chemical Industries, Ltd. |
Benzofurans as suppressors of neurodegeneration
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
PT997460E
(pt)
*
|
1998-10-28 |
2003-03-31 |
Lilly Co Eli |
Compostos benzotiofenos como agentes antitromboticos e seus intermediarios
|
|
ATE258934T1
(de)
|
1998-10-30 |
2004-02-15 |
Lilly Co Eli |
Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
|
|
ATE259802T1
(de)
*
|
1999-11-19 |
2004-03-15 |
Lilly Co Eli |
Verbindungen mit antithrombotischer wirkung
|
|
CA2444787A1
(en)
|
2001-05-22 |
2002-11-28 |
Eli Lilly And Company |
Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
|
|
WO2002094788A1
(en)
|
2001-05-22 |
2002-11-28 |
Eli Lilly And Company |
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
AU2002351412B2
(en)
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
|
EP1530470B9
(en)
*
|
2002-07-22 |
2010-04-07 |
Eli Lilly And Company |
Selective estrogen receptor modulators containing a phenylsulfonyl group
|
|
US7296361B2
(en)
*
|
2003-07-31 |
2007-11-20 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
ES2649737T5
(es)
|
2003-08-01 |
2021-07-07 |
Mitsubishi Tanabe Pharma Corp |
Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
|
|
AU2006212726C1
(en)
|
2005-02-14 |
2013-05-16 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
CA2699285C
(en)
|
2007-09-10 |
2016-12-13 |
Ahmed F. Abdel-Magid |
Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
IN2012DN03299A
(OSRAM)
|
2009-10-14 |
2015-10-23 |
Janssen Pharmaceutica Nv |
|
|
SG185525A1
(en)
|
2010-05-11 |
2012-12-28 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
|
AU2012241897C1
(en)
|
2011-04-13 |
2017-05-11 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
ES2570862T3
(es)
|
2011-12-15 |
2016-05-20 |
Bayer Ip Gmbh |
Benzotienil-pirrolotriazinas sustituidas y usos de las mismas en el tratamiento de cáncer
|
|
WO2013124316A1
(en)
|
2012-02-23 |
2013-08-29 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
|
WO2016132998A1
(ja)
*
|
2015-02-19 |
2016-08-25 |
Jnc株式会社 |
ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
CN114539273A
(zh)
|
2016-06-07 |
2022-05-27 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
HRP20241239T1
(hr)
|
2017-03-23 |
2024-12-06 |
Jacobio Pharmaceuticals Co., Ltd. |
Novi heterociklički derivati korisni kao shp2 inhibitori
|
|
WO2020063760A1
(en)
|
2018-09-26 |
2020-04-02 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as shp2 inhibitors
|